UVI3003 – 10 mg

Brand:
Cayman
CAS:
847239-17-2
Storage:
-20
UN-No:
Non-Hazardous - /

The receptors for retinoids, RARs and RXRs, form heterodimers with many other family members in order to control various physiological and pathological processes, including cancer and metabolic diseases. UVI3003 is a full antagonist of RXR that demonstrates potent, nanomolar binding affinity.{28139} At 1 µM, UVI3003 does not affect the corepressor interaction capacity of the RARα subunit in the RAR-RXR heterodimer configuration.{28139} This compound can be used to isolate the contribution of RXR to the function of RXR heterodimers.{28139,28140}  

 

SKU: - Category:

Description

A full antagonist of RXR that demonstrates potent, nanomolar binding affinity; does not affect the corepressor interaction capacity of the RARα subunit in the RAR-RXR heterodimer configuration


Formal name: 3-[4-hydroxy-3-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-3-(pentyloxy)-2-naphthalenyl]phenyl]-2-propenoic acid

Synonyms: 

Molecular weight: 436.6

CAS: 847239-17-2

Purity: ≥90%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Endocrinology & Metabolism|Hormones & Receptors|RARs, RORs, & RXRs